SecBot SecBot
PRESS-RELEASE ·Filed Mar 17, 2026

IMCR

Immunocore Holdings plc
NEUTRAL
Impact 5/10
Horizonweeks Processed8mo ago WireGlobeNewswire
Press release · Announcement
Actionable Insight • Neutral

Traders should monitor the actual data release after the April 19 presentation for survival rate trends, which could influence investor perception of KIMMTRAK’s durability and market positioning. Positive data may support valuation, especially given the lack of competing therapies.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$30.04
T+0 close · Mar 17, 2026 · via day close
Latest settled
−4.73%
T+60 · $28.62
Vs SPY
−16.25%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 18 $30.04entry
  2. T+1 · 8mo ago 0.00%α +0.27% · $30.04
  3. T+5 · 8mo ago +0.80%α +1.51% · $30.28
  4. T+20 · 7mo ago +4.46%α −1.59% · $31.38
  5. T+60 · 5mo ago −4.73%α −16.25% · $28.62
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Immunocore announced it will present five-year overall survival data from the KIMMTRAK Phase 3 trial in metastatic uveal melanoma at the 2026 AACR Annual Meeting. This represents the longest OS follow-up in a randomized trial for this patient population, potentially reinforcing KIMMTRAK's clinical benefit in a rare and aggressive cancer with limited treatment options.

Key Facts

  • Immunocore will present five-year overall survival data from the KIMMTRAK Phase 3 trial at AACR 2026.
  • Data comes from a randomized trial in HLA-A*02:01-positive patients with previously untreated metastatic uveal melanoma.
  • Presentation includes additional insights: subsequent treatments, treatment beyond progression, and prognostic factors.
  • KIMMTRAK is already approved in the U.S., EU, Canada, Australia, and the UK for this indication.
  • No financial results, revenue figures, or guidance updates were included in the release.

Financial Impact

Potential long-term commercial reinforcement of KIMMTRAK, but no immediate financial impact disclosed

revenuecommercial outlook

Risk Factors

  • Five-year OS data could show diminishing survival benefit or increased late toxicity, negatively impacting sentiment.
  • No new patient enrollment or trial expansion announced; commercial uptake remains limited by HLA-A*02:01 biomarker restriction.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3257672

US Market Status

Market Closed · Opens Wed (10h 27m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 17, 2026